Pages

Tuesday, November 29, 2022

Drug Channels News Roundup, November 2022: Mark Cuban vs. Elon Musk, Lessons from Semglee, Gen Z vs. Pharmacy Careers, 340B Transparency, and I ♥ the 90s

I hope everyone enjoyed the Thanksgiving holiday! Now that you’ve stretched your stomach, stretch your mind with some food for thought. In this issue:
  • Mark Cuban schools Elon Musk on PBMs
  • Market access lessons from Semglee
  • Gen Z rejects the pharmacy career path
  • A potent call for 340B transparency
Plus, get ready to love the ‘90s again!

P.S. Join my more than 34,000 LinkedIn followers for daily links to neat stuff. If you haven't quit Twitter, you can also find my daily posts at @DrugChannels on Twitter, where I have more than 15,500 followers.

Please join me for my upcoming live video webinar, Drug Channels Outlook 2023, on December 16, 2022, from 12:00 p.m. to 1:30 p.m. ET. Click here to learn more and sign up.

Friday, November 18, 2022

Engage Specialists in Their Workflow With GoodRx Provider Mode

Today’s guest post comes from Bansi Nagji, President of Healthcare at GoodRx.

Bansi explains how GoodRx Provider Mode delivers a prescription savings flow that offers health care professionals (HCPs) efficient access to the information they need at critical moments of care.

Click here to learn how GoodRx Provider Mode can help manufacturers reach and engage HCPs.

Read on for Bansi’s insights.

Tuesday, November 15, 2022

Behind the GoodRx-Express Scripts Partnership: How PBMs Profit from Discount Cards in Pharmacy Benefits

Last week, GoodRx announced that it would become the exclusive prescription discount card provider for the commercial beneficiaries of Cigna’s Express Scripts. Links below.

The rise of discount card pricing within pharmacy benefit plans is a positive development. Patients get access to market prices that can  be lower than their PBM’s contracted rate. All out-of-pocket spending with a discount card counts toward a patient's deductibles, and all prescription activity gets captured.

However, I suspect few people understand that placing discount cards within the pharmacy benefit enables a PBM to monetize a new fee stream from the card vendor. Below, I walk through this booming business and highlight some of the conflicts and contradictions underneath the coconuts.

I’ll cover what’s next for PBMs and discount cards during my upcoming live video webinar, Drug Channels Outlook 2023, on December 16, 2022, from 12:00 p.m. to 1:30 p.m. ET. Click here to learn more and sign up.

Friday, November 11, 2022

Cell and Gene Therapy Roundup: What the Road to Success Looks Like

Today’s guest post comes from Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen.

Lung-I discusses advancements in cell and gene therapy and explains how to tackle the challenges facing manufacturers, providers, and patients.

Click here to learn about AmerisourceBergen’s Cell and Gene Therapy solutions for biopharma companies, providers, and patients.

Read on for Lung-I’s insights.

Wednesday, November 09, 2022

Drug Channels Outlook 2023 (NEW Live Video Webinar)

Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for a new live video webinar:

Drug Channels Outlook 2023
Friday, December 16, 2022
12:00 p.m. to 1:30 p.m. ET.

This page describes the event and explains how to purchase a registration to the live event. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia.

WHAT YOU WILL LEARN

Join Dr. Fein as he helps you and your team get ready for 2023 by outlining key issues and uncertainties that will surely affect your planning. This event can be both a capstone of your annual learning and a touchpoint for the future. Dr. Fein will draw from exclusive information found in DCI’s industry economic reports.

During the event, Dr. Fein will share his latest thinking on a wide range of topics, including:
  • Update on the retail pharmact market
  • The Medicare Part D Redesign
  • What's next for the Inflation Reduction Act of 2022
  • Vertical integration and consolidation trends
  • PBM industry developments and government actions
  • Disruption from discount cards and cash-pay pharmacies
  • Predictions for biosimilar Humira competition
  • The latest on copay accumulators and maximizers
  • Likely 340B Drug Pricing Program developments
  • Hospitals and health systems in the pharmacy channel
  • The primary care M&A boom
  • And more!
As always, Dr. Fein will clearly distinguish his opinions and interpretations from the objective facts and data. PLUS: During the webinar, Dr. Fein will give participants an opportunity to unmute themselves and ask live questions. The webinar will last 90 minutes to accommodate audience questions.

After the event, every registrant will receive a link to download the complete slide deck and have an opportunity to watch a replay of the live event.

Read on for full details on pricing and registration.

Tuesday, November 08, 2022

The Consolidated Drug Channel and Cash-Pay Drugs: My Podcast with a16z's Julie Yoo

I recently joined Julie Yoo on Bio Eats World, a podcast from legendary venture capital firm Andreessen Horowitz (also known as "a16z"). Julie is a General Partner at Andreessen Horowitz.

We chatted about the current state of the U.S. drug channel, the roles and controversies around pharmacy benefit managers (PBMs), GoodRx, Mark Cuban’s cost-plus pharmacy, the 340B Drug Pricing Program, and much more. I also shared some thoughts on opportunities for entrepreneurs in such a consolidated space. The episode is about 36 minutes long.

The podcast audio is embedded below, along with links to the episode on major podcast platforms.

Enjoy!

P.S. Let me know if you’d like to see more audio/podcast content on Drug Channels.

Friday, November 04, 2022

Innovate4Outcomes: Collaborating to Solve Antimicrobial Resistance

Today’s guest post comes from Matthew Balogh, Head of Digital Marketing at Melinta Therapeutics.

Matt discusses the ongoing global problem of antimicrobial resistance (AMR). He suggests that lessons learned from the COVID-19 pandemic can inform both innovation in AMR therapies and our understanding of AMR.

To learn more about the global challenge of AMR and brainstorm solutions, request an invitation to Innovate4Outcomes®. This virtual event is presented by OptimizeRx in collaboration with Melina Therapeutics.

Read on for Matt’s insights.

Tuesday, November 01, 2022

Preferred Pharmacy Networks in 2023’s Medicare Part D Plans: Cigna, CVS Health, Humana, UnitedHealthcare, WellCare, and More

Open enrollment is under way for the 2023 Medicare Part D plans. Our exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that preferred cost sharing pharmacy networks will maintain their dominance as an established component of Part D benefit design.

For 2023:
  • 98% of stand-alone Medicare Part D prescription drug plans (PDP) will have a preferred network.
  • 52% of Medicare Advantage prescription drug (MA-PD) plans will have a preferred network.
Below, I provide historical data on preferred networks’ growth and update the top companies’ 2023 offerings.

The largest companies made only minor changes to their 2023 stand-alone plans, after streamlining their 2022 plans. I also update our analysis of the prevalence of preferred networks in three different types of MA-PD plans.

In upcoming articles, I’ll investigate what we can deduce from chain and independent pharmacies’ participation in the major 2023 preferred networks.

Friday, October 28, 2022

How the Therapy Warranty Model Shifts the Paradigm of Therapy Success

Today’s guest post comes from Brooks Wildasin, Vice President of Product Management at CareMetx.

Brooks introduces us to CareMetx’s specialty therapy warranty, a specialty patient outcome-based contract model. Download CareMetx’s 2022 Report: The Evolving Landscape of Digital Healthcare Hubs to learn more about digital hub services and CareMetx’s solutions that improve the patient journey.

Read on for Brooks’ insights.

Tuesday, October 25, 2022

Drug Channels News Roundup, October 2022: Mark Cuban on PBMs, Walgreens & 340B, Biosimilar Boom Update, Physicians vs. UM, and Wellness at Walgreens

Eeek! Time for my Halloween roundup of wicked Drug Channels’ tales. This month’s tricks and treats:
  • Eerie! Mark Cuban tells ghost stories about PBMs.
  • Shocking! Walgreens terrifies Wall Street with its 340B losses.
  • Vampiric! Sink your fangs into Amgen’s fantastic new report on the biosimilar boom
  • Wicked! Physicians think payers cast evil utilization management spells.
Plus, Walgreens launches a refreshing new wellness service.

P.S. Join my more than 33,000 LinkedIn followers for daily links to neat stuff. You can also find my daily posts at @DrugChannels on Twitter, where I have more than 15,400 followers.

Friday, October 21, 2022

Innovation Brings Unwavering Patient Support in a New Era of Specialty Medicine

Today’s guest post comes from Megan Marchal, Director of Specialty Pharmacy Strategy at CoverMyMeds.

Megan discusses upcoming specialty medication launches. As she explains, patients will need extra help to overcome the challenges of access, affordability, and adherence.

Click here to learn about CoverMyMeds' patient-centric technology solutions for specialty medications..

Read on for Megan’s insights.

Tuesday, October 18, 2022

How the Biosimilar Boom Boosts Drug Wholesalers’ Profits

The biosimilar boom for provider-administered drugs continues to accelerate. Net prices in therapeutic classes with biosimilar competition have declined by 60% or more over the past few years. Some major biological reference products have now lost a majority of their unit sales to their biosimilars.

As we explain below, this accelerating adoption also boosts profits for pharmaceutical wholesalers and specialty distributors—particularly when these channel participants can influence which biosimilar version a provider utilizes.

Below, we share our estimates for wholesalers’ gross margins for brand-name, generic, and biosimilar drugs. We then explain the channel dynamics behind biosimilar and generic drugs’ profits. We estimate that for 2022, generics and biosimilars accounted for only about 15% of wholesalers’ U.S. drug distribution revenues, but 77% of total gross profits from U.S. drug distribution.

Read on for the fun financial facts.

Monday, October 17, 2022

Informa Connect’s Trade & Channel Strategies Summit

Informa Connect’s Trade & Channel Strategies Summit
December 12-14, 2022 in Philadelphia, PA
www.informaconnect.com/trade

Don’t miss Informa Connect's Trade & Channel Strategies Summit, coming up December 12-14, 2022 in Philadelphia! Join your colleagues from across the industry and be part of critical, solution-focused discussions designed to help optimize distribution models and channel strategies driven by market dynamics, product types, site of care and reimbursement, all delivered by an expert speaking faculty.

View the agenda to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/trade for further details and to register. Drug Channels readers will save 10% off when they use code 22DRCH10 and register prior to November 11, 2022.*

You'll attend a Featured Session with Bill Roth, General Manager and Managing Partner, Blue Fin Group, An IntegriChain Company, as he covers Current and Future Trends Impacting Trade and Distribution, a Policy Address, a Wall Street Address, a Partnership Pavilion Panel (3PL, Distribution and Pharmacy), a Distribution Stakeholder Showcase, and an Update from NCPDP.

Additional sessions include coverage on:
  • Navigating regulatory reform in the trade & channel space
  • Building forward-thinking commercialization and channel strategies for patient affordability
  • Maximizing GTN impact
  • Future of value-based agreements, measurement, contracting and pull through
  • Innovative limited pharmacy networks
  • The Drug Supply Chain Security Act
  • Emerging distribution trends for a streamlined and efficient model
  • Migrating a primary care manufacturer to specialty channel strategies
  • Determining the best network for your product - distribution and dispensing partners
  • Navigating the payer space for specialty, rare and orphan diseases
  • Future of cell therapies and distribution considerations
  • The role of distributors in gene therapies
  • Current trends and changes impacting biosimilars and specialty generics
  • How to tailor a new launch strategy for biosimilars
  • And so much more!
Don’t miss the chance to unite with colleagues and master the complexities of pharmacy and distribution models to accelerate patient access!

View the agenda to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/trade for further details and to register. Drug Channels readers will save 10% off when they use code 22DRCH10 and register prior to November 11, 2022.*

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates or other offers. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net).

Friday, October 14, 2022

What Pharma Companies Can Expect From the Influx of Humira Biosimilars

Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT.

Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers.

To learn more, check out MMIT’s Strategic Launch Report & Evaluate Forecast solution.

Read on for Steve’s insights.

Thursday, October 13, 2022

Mapping the Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers: A 2022 Update

I conservatively estimate that I’ve created about 1,374,613 slides during my career. But there are two slides that people seem to appreciate the most.

One is my chart showing the key channel flows within the entire U.S. pharmaceutical distribution, payment, and reimbursement system.

The other is my mapping of the insurer/PBM/specialty pharmacy/provider organizations that now dominate U.S. drug channels. Below, I provide an updated version of this second chart that reflects some recent transactions and name changes. About half of all U.S. healthcare spending flows through the seven companies shown below.

These organizations are poised to exert greater control over patient access, sites of care/dispensing, and pricing. But as I note below, Federal Trade Commission chair Lina M. Khan has other ideas about these companies.

Tuesday, October 11, 2022

NEW: The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

I am pleased to announce our new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, available for purchase and immediate download.
We’re offering special discounted pricing if you order before October 21, 2022!

The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—our 13th edition— remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry.

This 2022-23 edition contains the most current financial and industry data along with detailed information about the strategies and market positions of the largest companies: AmerisourceBergen, Cardinal Health, and McKesson. It updates our annual analysis of each wholesaler’s business segments and underlying business profitability, based upon our proprietary economic models.

The notable new material in this 2022-23 edition includes three new sections:
  • Section 3.4.1. contains new data on hospital acquisitions and consolidation activity.
  • Section 6.1.6. examines how the Inflation Reduction Act could ultimately impact pharmaceutical wholesalers’ customers and business outlook.
  • We have updated our financial analyses based on the new reporting segments introduced by AmerisourceBergen and McKesson.
We also update sections that were introduced in recent editions, such as our estimates of wholesalers' profits from provider-administered biosimilar drugs.
If you would like to pay by corporate purchase order or check, please email Tamra Feldman. If you preordered the report, you should have already received an email with download instructions. Please contact us if you did not receive the email.

WHAT’S GOING ON

Twice a year, I spend my evenings and weekends writing two comprehensive, fact-based, and nonpartisan reports on drug channel economics. In some small way, I try to make the world a better and smarter place.

Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, lawyers, consultants, and more. So, you can find out what your customers, partners, and competitors are reading.

The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors is the only resource of its kind available anywhere. It offers 142 proprietary charts, exhibits, and data tables.

FOUR FUN FACTS
  • The 9 chapters are self-contained and do not need to be read in order. (Really!) There are loads of internal hyperlinks to help you navigate the document and customize it to your specific interests and priorities.
  • We are offering the option to download an additional PowerPoint file with images of all 150 exhibits. This popular option helps you share the insights and data with others in your organization. (The exhibits appear in all license versions. The PowerPoint file option is available only with the purchase of a corporate license.)
  • There are nearly 600 endnotes, most of which have hyperlinks to original source materials. These source materials offer a handy way to build your knowledge base beyond what’s included in the full report.
  • As usual, I have reluctantly stripped out the corny jokes and pop culture references.
If you have any questions (before or after reading the report), please email me.

Enjoy!

Friday, October 07, 2022

vitaCare From GoodRx Reimagines Prescription Services for a Wider Range of Patients and Treatments Than Traditional Hub Services (Guest Post)

Today’s guest post comes from Jon Lanznar, Chief Strategy Officer at vitaCare Prescription Services from GoodRx.

Jon discusses vitaCare, a pharmacy services platform acquired by GoodRx earlier this year. vitaCare helps patients understand coverage, identifies available savings opportunities, and facilitates communications between providers and payers. It also offers a path for filling a prescription, primarily through their network of third-party pharmacies.

Click here to learn more about vitaCare’s access and adherence solutions.

Read on for Jon’s insights.

Tuesday, October 04, 2022

Five Surprising Facts About GoodRx and the Discount Card Market

Last month, IQVIA quietly released a fascinating new report on discount cards. (Link below.) The research was sponsored by the Association for Accessible Medicines (AAM).

Below, I highlight three unexpected findings from the data regarding GoodRx’s market position, when people use discount cards, how much they save, and why PBMs should still be worried about this market.

There’s a lot to unpack about the growing discount card market. As you’ll see, this report provides valuable insights about a market that seems stacked against patients.

Friday, September 30, 2022

Building New Data Connections Helps Brands Lower Adherence Barriers

Today’s guest post comes from Kylie Hall, Director of Product Management at ConnectiveRx.

Kylie explains how new ways of harnessing patient data can transform the way pharmaceutical companies interact with patients and providers—and ultimately help improve adherence.

Click here to learn about the ConnectiveRx Enterprise Data Platform.

Read on for Kylie’s insights.

Tuesday, September 27, 2022

Drug Channels News Roundup, September 2022: Patients vs. SaveonSP, PBMs’ Oncology Exclusions, Medicare Advantage Winners, HRSA’s 340B Reveal, and New DCI Offerings

Autumn is here! Please savor these Drug Channels acorns that we’ve squirrelled away for you:
  • One patient’s troubling experience with SaveonSP
  • PBMs ramp up formulary exclusions for oncology drugs
  • The mega-players dominating Medicare Advantage
  • My 340B FOIA efforts yield change at HRSA!
Plus, two new resources from Drug Channels Institute.

P.S. Join my 32,000 LinkedIn followers for daily links to neat stuff. You can also find my daily posts at @DrugChannels on Twitter, where I have more than 15,200 followers.

Friday, September 23, 2022

Managing 340B, Medicaid Drug Discounts: Technology for Collaboration – Anywhere, Anytime

Today’s guest post comes from Lindsey Alves, Vice President of Customer Success at Kalderos.

Lindsey describes the challenges facing remote workers who manage government-managed drug discount programs. As she explains, all drug discount stakeholders require novel technology-enabled collaboration tools.

To learn more, register for Kalderos’ panel discussion, The Dreaded Duplicate Discounts: Collaborating in the New Hybrid Working Landscape. You can also schedule a meeting with Kalderos at the Informa Connect Medicaid Drug Rebate Conference, October 13, 2022, in Chicago.

Read on for Lindsey’s insights.

Wednesday, September 21, 2022

White Bagging Update 2022: Hospitals Battle to Boost Buy-and-Bill

The battle for control of the specialty patient continues.

In 2022, specialty pharmacies—via white, brown, and clear bagging—now constitute a meaningful share of the distribution channels for provider-administered oncology drugs.

However, buy-and-bill appears to have rebounded substantially at hospitals. As I explain below, this resurgence likely reflects the success of vertically-integrated hospital/specialty pharmacy/physician mega-systems against the large insurer/PBM/specialty pharmacy/provider mega-organizations.

Read on for full details and the latest data.

FYI: The material in today’s article is adapted from Chapter 3 of our forthcoming 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, now available to preorder at special introductory pricing.

Tuesday, September 20, 2022

Available for Preorder: The 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 11, 2022, Drug Channels Institute will release The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our thirteenth edition— remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry.

We are providing you with the opportunity to preorder this thoroughly updated and revised 2022-23 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive a download link before October 11.


You can pay online with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal. Click here to email us if you would like to pay by corporate purchase order or check.

Preorder and launch pricing discounts will be valid through October 21, 2022.

Friday, September 16, 2022

The Pulse of Electronic Benefit Verification Solutions: Know the Facts

Today’s guest post comes from Edward Hensley, Chief Commercial Officer at AssistRx.

Edward compares the pros and cons of electronic benefit verification using artificial intelligence, direct connectivity, or data connectivity. He also describes the circumstances where each solution provides the greatest value.

To learn more, download AssistRx’s free eBook: Specialty Drug Patient Support Programs: 2022 Progress Report.

Read on for Edward’s insights.

Wednesday, September 14, 2022

NEW: The Drug Channels 2023 Video Webinar Series

I invite you to join me for three new video webinars during 2023. These live, interactive events will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia.

During these events, I'll address the latest issues confronting the U.S. drug channel. Topics will be determined based on what’s happening—trends, policy changes, company announcements, and more. I’ll share DCI’s latest market data to help you stay on top of new developments. You will be able to use these events as both a capstone of your current learning and a touchpoint for the future.

The three events are scheduled for 12:00 p.m. to 1:30 p.m. ET on the following dates:
  • March 31, 2023
  • June 23, 2023
  • December 15, 2023 (Drug Channels Outlook 2024)
For 2023, we are offering a new Corporate Pricing option that will allow larger organizations to register hundreds of colleagues for one fixed price.


Read on for my video invitation and full details on pricing, including substantial discounts for multiple sites.

Tuesday, September 13, 2022

The Inflation Reduction Act: Three Unintended Consequences for Biosimilars, Health Plans, Providers, and Pharmacies

By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. 117-169).

Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to administer the IRA's lower pharmacy reimbursements.

I can only barely scratch the surface in this article, so feel free to share your own thoughts in the comments below or on social media.

At this point in our country’s history, you might think Congress would have learned the immutable law of 730-page bills: Legislate in haste, repent at leisure.

Friday, September 09, 2022

Patients At Risk As Healthcare Navigates Affordability

Today’s guest post comes from Kristina Crockett, Vice President of Product Management at CoverMyMeds.

Kristina discusses the affordability challenges that patients face in our complex and confusing healthcare system. She then explains how data and technology can help payers, manufacturers, and providers improve medication access.

To learn more about CoverMyMeds’ comprehensive affordability solutions, download Overcoming Medication Affordability Challenges with Patient-Centered Solutions.

Read on for Kristina’s insights.

Wednesday, September 07, 2022

The Biosimilar Boom and the Coming Humira Price War (Video)

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. Prices are dropping while adoption accelerates. In many therapeutic areas, biosimilars’ market share is approaching 80%. In the video below, I review these developments and discuss lessons from the launch of Semglee, the first interchangeable insulin.

I also offer some thoughts on 2023 and 2024. That’s when Humira, the best-selling drug in the U.S., will face multiple biosimilar competitors. Some—but likely not all—of these products will have interchangeability with Humira.

The video is excerpted from last month’s Specialty Drugs Update: Trends, Controversies, and Outlook video webinar. During the webinar, I speculated that net prices in the Humira category will be 70% or more below today’s prices. If you missed the live event, you can register to watch a replay and download the full slide deck.

Despite these positive recent developments, the just-passed Inflation Reduction Act (IRA) seems likely to disrupt the biosimilar market by altering launch strategies. However, the IRA won’t affect the coming Humira price war.

Enjoy!

Friday, August 26, 2022

Your Brand Just Got Added to a Must-Have Formulary: Now What?

Today’s guest post comes from Chris Dowd, Senior Vice President of Market Development at ConnectiveRx.

Chris discusses the benefits of using in-electronic health record (EHR) messaging to communicate formulary information to both healthcare providers and patients during the patient encounter. Click here to learn more about ConnectiveRx’s in-EHR messaging

You can also register for Your Brand Just Got Added to a Must-Have Payer Formulary, Now What?, a free webinar on September 29th at 1:00 P.M. ET.

Read on for Chris’ insights.

Tuesday, August 23, 2022

Drug Channels News Roundup, August 2022: Gov. Dean vs. Maximizers, Cancer vs. Copays, Specialty Drug Trends, Biosimilar Transitivity, and Dr. G. vs. PBMs

Our news-laden summer is coming to an end. Time to pack away your bathing suit, send the kids back to school, and cherish these curated curiosities that I combed from the Drug Channels coastline:
  • Howard Dean attacks patient-unfriendly cost shifting
  • Cancer patients’ views of copay assistance
  • My $0.02 on key specialty pharmacy trends
  • Evidence for biosimilar-to-biosimilar switching
Plus, Dr. Glaucomflecken takes on PBMs!

P.S. Join my more than 31,000 LinkedIn followers for daily links to neat stuff. You can also find my daily posts at @DrugChannels on Twitter, where I have more than 15,000 followers.

Monday, August 22, 2022

Informa Connect’s Copay, Reimbursement and Access Congress

Informa Connect’s Copay, Reimbursement and Access Congress
Hybrid Event | October 12-14 in Philadelphia, PA
www.informaconnect.com/copay

Exclusive Offer: Be sure to use your exclusive promo COPAYDC to save 10% off* of your registration

An important event for all aspects cost sharing, Copay, Reimbursement and Access Congress is back and better than ever! This year's event features a brand new look with the same great content, dedicated tracks, diverse and robust speaking faculty and greater networking opportunities. Now is the time to join to drive patient assistance, adherence and access forward—it’s all happening October 12-14.

Exclusive Offer: View the agenda and register today. Be sure to use your exclusive promo COPAYDC to save 10% off* of your registration.

Why should you attend this pivotal event?

Copay and cost sharing programs are growing continuously more complex. The recent enforcement actions surrounding cost sharing programs are evidence that the shifting market dynamics remain a deep concern and bring about many questions for access professionals.

How are you managing out-of-pocket costs for patients? Do you have clarity on the further of health policy? What is the impact of accumulator and maximizer program utilization on your organization?

In just two-and-a-half days, walk away with answers to these questions and more from experts from across the industry. You would be remiss not to join seasoned leaders, your peers and leading solution providers as they navigate marketplace trends and dive into the impact coupons, accumulators, maximizers, benefit design, innovation and drug pricing legislation have on patient affordability and out-of-pocket costs and provide critical insights on industry standards, forward-thinking strategies to optimize copay and cost sharing programs to accelerate access and commercialization and so much more.

Can’t miss content highlights:
  • Two Pre-Conference Workshops
    • Copay 101 Workshop
    • Product Launch and Commercialization Summit
  • Marketplace Trends Opening Panel
  • Advocacy Insights and Furthering Access to Care
  • Government Enforcement Trends Impacting Copay Assistance
  • Analyze the Effect, Impact and Utilization of Accumulator and Maximizer Programs
  • And more!
PLUS! Two Dedicated Tracks for Your Focus Area:

Innovative Copay Program Design and Utilization Management
  • Implementing Innovation to Drive Next Generation Copay Design
  • Legal Implications and Compliance for Copay Programs
  • Utilizing Copay Data to Drive Program Decisions and Product
  • And more!
  • Reimbursement Strategies and Contracting
    • Value-Based Contracting Frameworks and Considerations
    • HEOR, RWE and Their Roles in Reimbursement
    • Rebates and Reimbursement—Breaking Down the Pricing Strategy
    • And more!
    Exclusive Offer: View the agenda and register today. Be sure to use your exclusive promo COPAYDC to save 10% off* of your registration.

    Informa Connect will see you there!

    *Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply.
    The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net).